Efficacy of bezlotoxumab to prevent recurrent Clostridioides difficile infection (CDI) in patients with multiple prior recurrent CDI

Anaerobe. 2023 Nov 4:102788. doi: 10.1016/j.anaerobe.2023.102788. Online ahead of print.ABSTRACTAmong 23 patients with multiply recurrent Clostridiodies difficile infection (mrCDI) who received bezlotoxumab at the end of antibiotic treatment a sustained clinical response of 91 % at 30 days and 78 % at 90 days was achieved. Bezlotoxumab administered at the end of antibiotic treatment was effective in patients with mrCDI.PMID:37931679 | DOI:10.1016/j.anaerobe.2023.102788

Source: Anaerobe - November 6, 2023 Category: Microbiology Authors: Andrew M Skinner Xing Tan Colin Westman Thomas Birris Emily Drwiega Michael S Wang Stuart Johnson Source Type: research